News | November 16, 2023
Sanofi completes closing for potential first-in-class vaccine against ExPEC
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe
Next-generation booster vaccine candidate demonstrates potential to protect against COVID-19 variants of concern, including Omicron BA.1 and BA.2, with a favorable safety and tolerability profile
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
100% efficacy against severe Covid-19 disease and hospitalizations
Transaction adds to Sanofi pipeline a potential first-in-class vaccine candidate in acne vulgaris, a condition affecting millions of people worldwide
The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company
Subscribe To Our Newsletter & Stay Updated
